| ORIGINAL ARTICLE |
|
| Ahead of Print |
|
|
Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
Tarun Kumar Jain1, Guman Singh2, Sumit Goyal2, Ajay Yadav3, Dinesh Yadav4, Nitin Khunteta4, Hemant Malhotra3
1 Department of Nuclear Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
2 Department of Radiation Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
3 Department of Medical Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
4 Department of Surgical Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
Correspondence Address:
Tarun Kumar Jain,
Department of Nuclear Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur - 302 022, Rajasthan
India
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/wjnm.WJNM_95_20
|
|
|
Posttreatment detection of residual/recurrence disease in the head and neck cancers is not an easy task. Treatment induces changes create difficulties in diagnosis on conventional imaging (computed tomography [CT], magnetic resonance imaging) as well as macroscopic inspection (direct laryngoscopy). Hence, we evaluate the diagnostic performance of contract-enhanced F-18 fluorodeoxyglucose positron emission tomography (FDG PET)/CT in restaging of laryngeal carcinoma Postchemotherapy-surgery and/or radiation therapy. We retrospectively analyzed patients of carcinoma larynx (n = 100) who has completed treatment and were referred for FDG PET/CT. Two reviewers performed image analysis to determine recurrence at primary site and/lymph nodes and distant metastases. Receiver operating characteristic (ROC) was used to determine the maximum standardized uptake value (SUV max ) cut off for disease detection. Histopathological examination and clinical or imaging follow-up were taken as gold standard for recurrence. One hundred laryngeal carcinoma patients with mean age of 57.2 years (range of 40-76) were included in the present study. Among the 100 patients, 96 were male and remaining 4 were female. The average interval between completion of treatment and FDG PET/CT scan was 8.5 months (minimum 6 months). Of the 100 patients, FDG PET/CT detected FDG avid lesions in 66 patients. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of FDG PET/CT for residual/recurrence disease detection was 90.3%, 73.7%, 84.8%, 82.3%, and 84.0%, respectively (P < 0.05). In addition, in 10 patients, metachronous primaries were detected (lung-4, thyroid-2, tongue, colon, esophagus, and lymphoma-one each). On ROC curve analysis, SUVmax >6.1 had sensitivity and specificity of 80.6% and 94.7% respectively for detection of recurrent/metastatic disease. FDG PET/CT demonstrates high diagnostic accuracy for detection of residual/recurrent disease in treated laryngeal cancer patients and our findings suggest that this imaging modality should be the first-line diagnostic investigation in this cohort of patients. |
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 31 | | | PDF Downloaded | 3 |
|
Users Online: 194 
Search Pubmed for